RxLogix Successfully Expands the European Medicines Agency PV Platform, Seamlessly Onboarding 31 National Competent Authorities

We are pleased to announce that the European Medicines Agency (EMA) has successfully expanded and onboarded 31 National Competent Authorities (NCA’s) on PV Signal and PV Reports, our industry-leading platform specifically supporting signal detection, analytics, and signal validation.

In 2025, EMA successfully implemented an advanced safety surveillance platform powered by RxLogix technology. This implementation represented a major milestone, for EMA’s adoption of next-generation tools that support pharmacovigilance and public health across the European Union.

Onboarding the NCA’s is another major milestone in regulatory drug safety that strengthens Europe’s safety surveillance infrastructure and demonstrates the scalability of the RxLogix Unified PV Platform.

This milestone demonstrates that PV platforms must do far more than process safety data. They must operate as national and multinational regulatory infrastructure capable of supporting safety surveillance across multiple health authorities. Delivering integrated signal detection, data analysis and evaluation, and enterprise data management while simultaneously onboarding every European National Competent Authority validates the maturity, scalability, and operational resilience of the RxLogix Unified PV Platform.

The implementation required extensive coordination across multiple technical and business teams while ensuring uninterrupted regulatory operations and maintaining quality standards. This achievement further differentiates RxLogix as one of the few PV technology companies capable of operating at the highest levels of global regulatory complexity, demonstrating its ability to deliver regulator-scale PV programs, execute complex upgrades and expansions without disrupting critical safety operations, and support continuous collaboration and proactive performance monitoring.

EMA and NCA’s will now operate on a single integrated platform that provides a dynamic environment for data mining and analytics, enabling effective signal detection, pattern identification, and recognition of emerging safety trends from one integrated platform. This demonstrates enterprise-scale execution across signal detection, data analysis, and centralized safety data management, while highlighting RxLogix’s proven delivery capability, scalability, and commitment to modernization.

According to Raj More, Founder & CEO of RxLogix, “Successfully supporting the European Medicines Agency and all National Competent Authorities represents far more than a technology expansion, it validates a new standard for modern PV infrastructure. This milestone demonstrates that the future of drug safety lies in unified, intelligent platforms that seamlessly integrate signal detection, regulatory reporting, and enterprise data management at unprecedented scale. As regulatory expectations continue to evolve and the complexity of global drug safety increases, organizations will need platforms that are not only compliant, but resilient, scalable, and trusted to support regulatory decision-making across national and international ecosystems. We are proud that RxLogix is helping shape that future.”

About RxLogix Corporation
RxLogix is the complete drug safety platform, powered by Agentic AI and built exclusively for drug safety. It supports the entire PV lifecycle on a single foundation, spanning case management, aggregate reporting, signal detection, compliance, and lifecycle surveillance. Proven AI and automation improve quality, increase productivity, and reduce total cost of ownership. RxLogix is trusted in the world’s most demanding regulatory environments, with deployments across 105+ organizations, including five of the world’s ten largest pharmaceutical companies and two leading regulatory agencies, with 15 years of inspection-ready performance.

Complete confidence. Proven at scale.
Learn more at www.rxlogix.com